Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
SAR-131675
CHF 0.00
In stock
SYN-1165-M0011 mgCHF 270.00
SYN-1165-M0055 mgCHF 546.00
SYN-1165-M01010 mgCHF 858.00
SYN-1165-M05050 mgINQ
SYN-1165-M100100 mgINQ
Product Details | |
---|---|
Synonyms | SAR131675 |
Product Type | Chemical |
Properties | |
Formula | C18H22N4O4 |
MW | 358.4 |
CAS | 1092539-44-0 |
Purity Chemicals | ≥95% |
Appearance | Solid. |
Solubility | Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol. |
Declaration | Manufactured by SynKinase. |
Other Product Data |
Target: VEGFR-3 | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
InChi Key | PFMPOBVAYMTUOX-GOSISDBHSA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS | Download PDF |
Product Specification Sheet | |
Datasheet | Download PDF |
Description
SAR131675 is a potent and selective VEGFR-3 inhibitor. It inhibited VEGFR-3 tyrosine kinase activity and VEGFR-3 autophosphorylation in HEK cells with IC(50) values of 20 and 45nM, respectively. SAR131675 dose dependently inhibited the proliferation of primary human lymphatic cells, induced by the VEGFR-3 ligands VEGFC and VEGFD, with an IC(50) of about 20nM. SAR131675 was found to be highly selective for VEGFR-3 versus 107 receptors, enzymes, ion channels, and 65 kinases. However, it was moderately active on VEGFR-2 with a VEGFR-3/VEGFR-2 ratio of about 10. SAR131675 had no antiproliferative activity on a panel of 30 tumors and primary cells, further showing its high specificity and indicating that SAR131675 is not a cytotoxic or cytostatic agent.
Product References
- SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities: A. Alam, et al.; Mol. Cancer Ther. 11, 1637 (2012)